Design, synthesis and anticancer evaluation of substituted aryl-1,3-oxazole incorporated pyrazole-thiazole derivatives

IF 2.218 Q2 Chemistry

Chemical Data Collections Pub Date : 2024-03-01 DOI:10.1016/j.cdc.2024.101127

P. Venkata Ramana Reddy , E. Shivakumar , Dittakavi Ramachandran

{"title":"Design, synthesis and anticancer evaluation of substituted aryl-1,3-oxazole incorporated pyrazole-thiazole derivatives","authors":"P. Venkata Ramana Reddy , E. Shivakumar , Dittakavi Ramachandran","doi":"10.1016/j.cdc.2024.101127","DOIUrl":null,"url":null,"abstract":"<div>A new library of different types of aryl ring attached pyrazole-thiazole-oxazoles (11a-j) was prepared and their structures were characterized by 1HNMR, 13CNMR and mass spectral data. Further, these compounds were evaluated for anticancer effects towards a panel of four human cancer cell lines including SiHa (cervix cancer), A549 (lung cancer), MCF-7 (breast cancer) and Colo-205 (colon cancer) by the MTT method, with etoposide used as a reference drug. Most of the tested compounds exhibited good anticancer activity with IC50 values ranging from 0.13±0.046 µM to 18.6 ± 6.34 µM and the reference drug showed values ranging from 0.14 ± 0.017 µM to 3.11±0.11 µM, respectively. Among these compounds 11e, 11f, 11 g and 11 h displayed more potent anticancer activity as etoposide. All compounds showed selective cytotoxicity against cancer cells but not against normal Vero cells (IC50 = >24 µM), justifying the designing approach to develop a selective anticancer agent.</div>","PeriodicalId":269,"journal":{"name":"Chemical Data Collections","volume":"51 ","pages":"Article 101127"},"PeriodicalIF":2.2180,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Data Collections","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405830024000156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Chemistry","Score":null,"Total":0}

引用次数: 0

Abstract

A new library of different types of aryl ring attached pyrazole-thiazole-oxazoles (11a-j) was prepared and their structures were characterized by ¹HNMR, ¹³CNMR and mass spectral data. Further, these compounds were evaluated for anticancer effects towards a panel of four human cancer cell lines including SiHa (cervix cancer), A549 (lung cancer), MCF-7 (breast cancer) and Colo-205 (colon cancer) by the MTT method, with etoposide used as a reference drug. Most of the tested compounds exhibited good anticancer activity with IC₅₀ values ranging from 0.13±0.046 µM to 18.6 ± 6.34 µM and the reference drug showed values ranging from 0.14 ± 0.017 µM to 3.11±0.11 µM, respectively. Among these compounds 11e, 11f, 11 g and 11 h displayed more potent anticancer activity as etoposide. All compounds showed selective cytotoxicity against cancer cells but not against normal Vero cells (IC₅₀ = >24 µM), justifying the designing approach to develop a selective anticancer agent.

Abstract Image

查看原文本刊更多论文

作为抗癌剂的取代芳基-1,3-恶唑并入吡唑-噻唑衍生物的设计、合成和抗癌评估

制备了一个新的不同类型芳基环连接吡唑-噻唑-噁唑（11a-j）化合物库，并通过 1HNMR、13CNMR 和质谱数据对其结构进行了表征。此外，还采用 MTT 法评估了这些化合物对四种人类癌细胞株（包括 SiHa（宫颈癌）、A549（肺癌）、MCF-7（乳腺癌）和 Colo-205（结肠癌））的抗癌效果，并以依托泊苷作为参照药物。大多数受试化合物都表现出良好的抗癌活性，IC50 值从 0.13±0.046 µM 到 18.6 ± 6.34 µM，参比药物的 IC50 值从 0.14 ± 0.017 µM 到 3.11±0.11 µM。在这些化合物中，11e、11f、11 g 和 11 h 与依托泊苷相比具有更强的抗癌活性。所有化合物对癌细胞都显示出选择性细胞毒性，但对正常 Vero 细胞却没有（IC50 = >24 µM），这证明了开发选择性抗癌剂的设计方法是正确的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemical Data Collections Chemistry-Chemistry (all)

CiteScore

6.10

自引率

0.00%

发文量

169

审稿时长

24 days

期刊介绍： Chemical Data Collections (CDC) provides a publication outlet for the increasing need to make research material and data easy to share and re-use. Publication of research data with CDC will allow scientists to: -Make their data easy to find and access -Benefit from the fast publication process -Contribute to proper data citation and attribution -Publish their intermediate and null/negative results -Receive recognition for the work that does not fit traditional article format. The research data will be published as ''data articles'' that support fast and easy submission and quick peer-review processes. Data articles introduced by CDC are short self-contained publications about research materials and data. They must provide the scientific context of the described work and contain the following elements: a title, list of authors (plus affiliations), abstract, keywords, graphical abstract, metadata table, main text and at least three references. The journal welcomes submissions focusing on (but not limited to) the following categories of research output: spectral data, syntheses, crystallographic data, computational simulations, molecular dynamics and models, physicochemical data, etc.